ALCAM Mediates DC Migration Through Afferent Lymphatics and Promotes Allospecific Immune Reactions

Ann Helen Willrodt, Ann Charlott Salabarria, Philipp Schineis, Desislava Ignatova, Morgan Campbell Hunter, Martina Vranova, Alexandra M. Golding-Ochsenbein, Elena Sigmund, Annatina Romagna, Verena Strassberger, Marina Fabbi, Silvano Ferrini, Claus Cursiefen, Dario Neri, Emmanuella Guenova, Felix Bock, Cornelia Halin

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Activated leukocyte cell adhesion molecule (ALCAM, CD166) is a cell adhesion molecule of the immunoglobulin superfamily and has been implicated in diverse pathophysiological processes including T cell activation, leukocyte trafficking, and (lymph)angiogenesis. However, exploring the therapeutic potential of ALCAM blockade in immune-mediated inflammatory disorders has been difficult due to the lack of antibodies with blocking activity toward murine ALCAM. In this study, we identified and characterized a monoclonal antibody with high affinity and specificity for murine ALCAM. This antibody reduced in vitro T cell activation induced by antigen-presenting dendritic cells (DCs) as well as (trans)migration of murine DCs across lymphatic endothelial monolayers. Moreover, it reduced emigration of DCs from in vitro-cultured human skin biopsies. Similarly, antibody-based blockade of ALCAM reduced (lymph)angiogenic processes in vitro and decreased developmental lymphangiogenesis in vivo to levels observed in ALCAM-deficient mice. Since corneal allograft rejection is an important medical condition that also involves (lymph)angiogenesis, DC migration and T cell activation, we investigated the therapeutic potential of ALCAM blockade in murine corneal disease. Blocking ALCAM lead to DC retention in corneas and effectively prevented corneal allograft rejection. Considering that we also detected ALCAM expression in human corneal DCs and lymphatics, our findings identify ALCAM as a potential novel therapeutic target in human corneal allograft rejection.

Original languageEnglish
Article number759
Number of pages16
JournalFrontiers in Immunology
Volume10
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Activated-Leukocyte Cell Adhesion Molecule
Dendritic Cells
Cell Movement
Lymph
Allografts
CD27 Antigens
Corneal Diseases
Lymphangiogenesis
T-Lymphocytes
Blocking Antibodies
Antibodies
Emigration and Immigration
Cell Adhesion Molecules
Antigen-Presenting Cells
Cornea

Keywords

  • ALCAM
  • allograft rejection
  • blocking antibody
  • cornea
  • DC migration
  • dendritic Cell (DC)
  • lymphangiogenesis
  • lymphatic vessel

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Willrodt, A. H., Salabarria, A. C., Schineis, P., Ignatova, D., Hunter, M. C., Vranova, M., ... Halin, C. (2019). ALCAM Mediates DC Migration Through Afferent Lymphatics and Promotes Allospecific Immune Reactions. Frontiers in Immunology, 10, [759]. https://doi.org/10.3389/fimmu.2019.00759

ALCAM Mediates DC Migration Through Afferent Lymphatics and Promotes Allospecific Immune Reactions. / Willrodt, Ann Helen; Salabarria, Ann Charlott; Schineis, Philipp; Ignatova, Desislava; Hunter, Morgan Campbell; Vranova, Martina; Golding-Ochsenbein, Alexandra M.; Sigmund, Elena; Romagna, Annatina; Strassberger, Verena; Fabbi, Marina; Ferrini, Silvano; Cursiefen, Claus; Neri, Dario; Guenova, Emmanuella; Bock, Felix; Halin, Cornelia.

In: Frontiers in Immunology, Vol. 10, 759, 01.01.2019.

Research output: Contribution to journalArticle

Willrodt, AH, Salabarria, AC, Schineis, P, Ignatova, D, Hunter, MC, Vranova, M, Golding-Ochsenbein, AM, Sigmund, E, Romagna, A, Strassberger, V, Fabbi, M, Ferrini, S, Cursiefen, C, Neri, D, Guenova, E, Bock, F & Halin, C 2019, 'ALCAM Mediates DC Migration Through Afferent Lymphatics and Promotes Allospecific Immune Reactions', Frontiers in Immunology, vol. 10, 759. https://doi.org/10.3389/fimmu.2019.00759
Willrodt, Ann Helen ; Salabarria, Ann Charlott ; Schineis, Philipp ; Ignatova, Desislava ; Hunter, Morgan Campbell ; Vranova, Martina ; Golding-Ochsenbein, Alexandra M. ; Sigmund, Elena ; Romagna, Annatina ; Strassberger, Verena ; Fabbi, Marina ; Ferrini, Silvano ; Cursiefen, Claus ; Neri, Dario ; Guenova, Emmanuella ; Bock, Felix ; Halin, Cornelia. / ALCAM Mediates DC Migration Through Afferent Lymphatics and Promotes Allospecific Immune Reactions. In: Frontiers in Immunology. 2019 ; Vol. 10.
@article{508acbc3832a45c3b925aced47cd19f2,
title = "ALCAM Mediates DC Migration Through Afferent Lymphatics and Promotes Allospecific Immune Reactions",
abstract = "Activated leukocyte cell adhesion molecule (ALCAM, CD166) is a cell adhesion molecule of the immunoglobulin superfamily and has been implicated in diverse pathophysiological processes including T cell activation, leukocyte trafficking, and (lymph)angiogenesis. However, exploring the therapeutic potential of ALCAM blockade in immune-mediated inflammatory disorders has been difficult due to the lack of antibodies with blocking activity toward murine ALCAM. In this study, we identified and characterized a monoclonal antibody with high affinity and specificity for murine ALCAM. This antibody reduced in vitro T cell activation induced by antigen-presenting dendritic cells (DCs) as well as (trans)migration of murine DCs across lymphatic endothelial monolayers. Moreover, it reduced emigration of DCs from in vitro-cultured human skin biopsies. Similarly, antibody-based blockade of ALCAM reduced (lymph)angiogenic processes in vitro and decreased developmental lymphangiogenesis in vivo to levels observed in ALCAM-deficient mice. Since corneal allograft rejection is an important medical condition that also involves (lymph)angiogenesis, DC migration and T cell activation, we investigated the therapeutic potential of ALCAM blockade in murine corneal disease. Blocking ALCAM lead to DC retention in corneas and effectively prevented corneal allograft rejection. Considering that we also detected ALCAM expression in human corneal DCs and lymphatics, our findings identify ALCAM as a potential novel therapeutic target in human corneal allograft rejection.",
keywords = "ALCAM, allograft rejection, blocking antibody, cornea, DC migration, dendritic Cell (DC), lymphangiogenesis, lymphatic vessel",
author = "Willrodt, {Ann Helen} and Salabarria, {Ann Charlott} and Philipp Schineis and Desislava Ignatova and Hunter, {Morgan Campbell} and Martina Vranova and Golding-Ochsenbein, {Alexandra M.} and Elena Sigmund and Annatina Romagna and Verena Strassberger and Marina Fabbi and Silvano Ferrini and Claus Cursiefen and Dario Neri and Emmanuella Guenova and Felix Bock and Cornelia Halin",
year = "2019",
month = "1",
day = "1",
doi = "10.3389/fimmu.2019.00759",
language = "English",
volume = "10",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Media S.A.",

}

TY - JOUR

T1 - ALCAM Mediates DC Migration Through Afferent Lymphatics and Promotes Allospecific Immune Reactions

AU - Willrodt, Ann Helen

AU - Salabarria, Ann Charlott

AU - Schineis, Philipp

AU - Ignatova, Desislava

AU - Hunter, Morgan Campbell

AU - Vranova, Martina

AU - Golding-Ochsenbein, Alexandra M.

AU - Sigmund, Elena

AU - Romagna, Annatina

AU - Strassberger, Verena

AU - Fabbi, Marina

AU - Ferrini, Silvano

AU - Cursiefen, Claus

AU - Neri, Dario

AU - Guenova, Emmanuella

AU - Bock, Felix

AU - Halin, Cornelia

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Activated leukocyte cell adhesion molecule (ALCAM, CD166) is a cell adhesion molecule of the immunoglobulin superfamily and has been implicated in diverse pathophysiological processes including T cell activation, leukocyte trafficking, and (lymph)angiogenesis. However, exploring the therapeutic potential of ALCAM blockade in immune-mediated inflammatory disorders has been difficult due to the lack of antibodies with blocking activity toward murine ALCAM. In this study, we identified and characterized a monoclonal antibody with high affinity and specificity for murine ALCAM. This antibody reduced in vitro T cell activation induced by antigen-presenting dendritic cells (DCs) as well as (trans)migration of murine DCs across lymphatic endothelial monolayers. Moreover, it reduced emigration of DCs from in vitro-cultured human skin biopsies. Similarly, antibody-based blockade of ALCAM reduced (lymph)angiogenic processes in vitro and decreased developmental lymphangiogenesis in vivo to levels observed in ALCAM-deficient mice. Since corneal allograft rejection is an important medical condition that also involves (lymph)angiogenesis, DC migration and T cell activation, we investigated the therapeutic potential of ALCAM blockade in murine corneal disease. Blocking ALCAM lead to DC retention in corneas and effectively prevented corneal allograft rejection. Considering that we also detected ALCAM expression in human corneal DCs and lymphatics, our findings identify ALCAM as a potential novel therapeutic target in human corneal allograft rejection.

AB - Activated leukocyte cell adhesion molecule (ALCAM, CD166) is a cell adhesion molecule of the immunoglobulin superfamily and has been implicated in diverse pathophysiological processes including T cell activation, leukocyte trafficking, and (lymph)angiogenesis. However, exploring the therapeutic potential of ALCAM blockade in immune-mediated inflammatory disorders has been difficult due to the lack of antibodies with blocking activity toward murine ALCAM. In this study, we identified and characterized a monoclonal antibody with high affinity and specificity for murine ALCAM. This antibody reduced in vitro T cell activation induced by antigen-presenting dendritic cells (DCs) as well as (trans)migration of murine DCs across lymphatic endothelial monolayers. Moreover, it reduced emigration of DCs from in vitro-cultured human skin biopsies. Similarly, antibody-based blockade of ALCAM reduced (lymph)angiogenic processes in vitro and decreased developmental lymphangiogenesis in vivo to levels observed in ALCAM-deficient mice. Since corneal allograft rejection is an important medical condition that also involves (lymph)angiogenesis, DC migration and T cell activation, we investigated the therapeutic potential of ALCAM blockade in murine corneal disease. Blocking ALCAM lead to DC retention in corneas and effectively prevented corneal allograft rejection. Considering that we also detected ALCAM expression in human corneal DCs and lymphatics, our findings identify ALCAM as a potential novel therapeutic target in human corneal allograft rejection.

KW - ALCAM

KW - allograft rejection

KW - blocking antibody

KW - cornea

KW - DC migration

KW - dendritic Cell (DC)

KW - lymphangiogenesis

KW - lymphatic vessel

UR - http://www.scopus.com/inward/record.url?scp=85065414731&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065414731&partnerID=8YFLogxK

U2 - 10.3389/fimmu.2019.00759

DO - 10.3389/fimmu.2019.00759

M3 - Article

C2 - 31031759

AN - SCOPUS:85065414731

VL - 10

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

M1 - 759

ER -